Objective Very late stent thrombosis (VLST) remains an unresolved problem, and recent reports have indicated that VLST onset can occur in patients treated with both drug-eluting stents (DES) and bare metal stents (BMS). We evaluated the causes of VLST using optical coherence tomography (OCT). Methods OCT was performed in 22 patients (12 DES-treated patients, 10 BMS-treated patients). Because two instances of VLST occurred simultaneously in one case in the DES group, the DES group comprised 13 lesions, while the BMS group comprised 10 lesions. All struts were counted in each frame, and the proportion of uncovered or malapposed struts was calculated based on the overall number of struts in the stent. Results The interval from stent implantation to VLST onset was significantly longer in the BMS group. The proportion of uncovered struts and the ratio of malapposed struts were significantly higher in the DES group than in the BMS group. The OCT analysis demonstrated intimal hyperplasia or intimal disruption in all patients in the BMS group. However, in the DES group, severe hyperplasia and/or neoatherosclerosis was observed in only eight lesions (61.5%), while uncovered and malapposed struts were involved in the other lesions. Conclusion In most BMS-treated lesions, it appeared that VLST was caused by the occurrence of neoatherosclerosis after stent implantation. The causes of VLST in DES-treated lesions are more various and complicated than those observed for BMS-treated lesions.
Introduction
The popularization of drug-eluting stents (DES) has led to a decrease in the frequency of in-stent restenosis (ISR). However, very late stent thrombosis (VLST), which was first reported in 2004, remains an unresolved problem associated with DES (1, 2) . Several large-scale registries have reported that the frequency of stent thrombosis post-DES implantation is 0.36-0.6% each year, with no attenuation observed within a five-year follow-up period (3) (4) (5) . Recent re-ports regarding bare-metal stents (BMS) have indicated that VLST onset can occur more than five years post-stent implantation (6) (7) (8) (9) .
Because the onset of VLST is rare and a serious major cardiac event, identifying its causes is of great clinical significance. Intimal disruption has been indicated to be a possible mechanism of VLST (7) . In recent years, intravascular imaging devices have gradually revealed additional causes of VLST. For example, it has been indicated that uncovered struts (delayed healing) and malapposed struts (incomplete stent apposition) play a role in the development of post-DES implantation VLST (10) (11) (12) (13) (14) (15) (16) . However, until recently, few studies have evaluated the mechanisms of VLST using imaging devices. Of 23 patients that developed VLST and were treated at the two hospitals targeted in this study, we evaluated 22 patients who underwent optical coherence tomography (OCT).
Materials and Methods

Subjects
Twenty-three patients with acute coronary syndrome (ACS) that occurred at least one year after stent implantation were transported to either Tsuchiya General Hospital or Hiroshima City Asa Hospital between September 2010 and December 2012. During the same period, 787 emergent percutaneous coronary intervention (PCI) procedures for acute coronary syndrome (ACS) were performed at these two hospitals. The definition of VLST was based on the Academic Research Consortium (ARC) definition (17) . We included only those patients presenting with acute myocardial infarction or unstable angina who exhibited stent thrombosis on thrombectomy. The patients underwent emergency coronary angiography (CAG), which showed either complete or subacute obstruction at the site of stent insertion. This retro-spective study investigated 22 patients (23 lesions); one patient developed hemodynamic instability and was unable to undergo OCT and was thus excluded from the study.
The DES group comprised 12 patients and the BMS group comprised 10 patients. Because two instances of VLST occurred simultaneously in one case in the DES group, the DES group comprised 13 lesions, while the BMS group comprised 10 lesions.
All subjects gave their informed consent prior to undergoing CAG, PCI and OCT. This retrospective study was approved by the ethics committees of both hospitals.
CAG and PCI
Routine CAG was performed. A 6-Fr sheath using a 6-Fr guide catheter was inserted from the radial, brachial and femoral arteries. In the 10 DES-treated lesions and five BMS-treated lesions, thrombectomy was performed once the guidewire had passed through the lesions, and OCT was conducted after contrast confirmed a thrombolysis in myocardial infarction (TIMI) 3 flow. In the remaining eight lesions, aspiration was not performed because a TIMI 3 flow was confirmed just after the guidewire passed through the lesion. Among the patients with severe stenosis for which performing OCT was considered difficult, OCT was conducted after aspiration thrombectomy and pre-dilatation with 2.6±0.4 3.1±0.3 0.020 Pts: patients, DES: drug-eluting stents, BMS: bare metal stent, PCI: percutaneous coronary intervention, VLST: very late stent thrombosis SES: sirolimus-eluting stents, PES: paclitaxel-eluting stent, QCA: quantitative coronary angiography, RD: reference vessel diameter, %DS: % diameter stenosis, MLD: minimum lumen diameter a 1.5-mm balloon. In three DES-treated lesions and four BMS-treated lesions, thrombolysis was added according to the operator's discretion. In patients with a delayed coronary flow even after pre-dilation with a 1.5-mm balloon, we performed OCT according to the previously reported method (18) . After passing a guidewire through the target lesion, we confirmed that the OCT catheter was able to pass through the lesion without problems. Once this was confirmed, the OCT catheter was retracted to a position proximal to the target lesion. Once the system settings were prepared, dextran or contrast medium was injected into the target coronary artery. The OCT catheter was then passed through the target lesion, and, as soon as positioning was complete, pullback was initiated. When pullback was complete, the OCT catheter was retracted into the guide catheter. In addition, in patients with massive thrombi in the VLST lesions, intracoronary thrombolysis was performed at the operator's discretion. After obtaining the OCT findings, PCI was performed. The selection of the PCI strategy was made at the operator's discretion.
A quantitative coronary angiography (QCA) was conducted using a QAngio XA 7.1 (Medis; Medical Imaging Systems, Leiden, The Netherlands).
OCT
OCT was performed using either an M3 or ILUMIEN TM system (LightLab Imaging, Inc., Westford, USA). The frame rate was 20 frames and 100 frames for the M3 and ILUMIEN TM systems, respectively. The pull-back speed was 1.5 mm/sec for the M3 system and 20 mm/sec for the ILUMIEN TM system. Either dextran or contrast agent was used to wash out the blood flow when performing OCT. The entire length of the stent was analyzed.
OCT analysis
In this study, we classified the strut form into five patterns (A, B, C, D and E) based on the report by Miyazaki et al. and assessed uncovered struts (D, E) and malapposed struts (C, E) (19) ( Fig. 1 ). An uncovered strut was defined as strut in which the stent surface was not covered by a tissue layer, and a malapposed strut was defined as a strut that was separated from the vascular wall (sirolimus-eluting stent ! 160 μm; paclitaxel-eluting stent ! 130 μm; NIR stent ! 99 μm; Multi-Link stent, Multi-Link plus, Multi-Link vision, Palmaz-schatz ! 61 μm). All struts were counted in each frame, and the proportion of uncovered or malapposed struts was calculated based on the overall number of struts in the stent. When 10% or more struts were uncovered or malapposed, the patient was defined as having severe uncovered or severe malapposed struts, respectively. The OCT findings were evaluated by two observers; when their opinions differed, they either held a discussion until a consensus was reached, or a third observer made the decision. The tissue structure within the stents was classified as homogeneous, heterogeneous or layered based on the OCT findings. An unknown tissue structure was defined as mixed tissue that was difficult to classify as homogeneous, heterogeneous or layered.
A thrombus was defined as an irregular projection (accompanied by attenuation, red thrombus; not accompanied by attenuation, white thrombus) within the lumen (! 250 μm). We evaluated the percent plaque area within the minimal lumen area (MLA) site, and severe intimal hyperplasia was defined as a percent plaque area (X-MLA/X) of ! 60% (X: target lesion stent area). Intimal disruption was defined as rupture of the fibrous cap, allowing passage between the lumen and lipid-laden neointima, and neoatherosclerosis was defined as an atheromatous change in the neointimal tissue (including both lipid-rich and fibrous plaque) within the stented segment.
Statistical analysis
All variables are expressed as the mean ± SD. Continuous variables were compared between groups using the unpaired t-test, and categorical variables were compared using the χ 2 method. Probability was considered to be significant at a level of p<0.05. The statistical analyses were conducted using the JMP5.1.1 software package (SAS Institute Inc., Cary, USA). Table 1 shows the patient and lesion characteristics of the 12 patients (13 lesions) who developed post-DES implantation VLST and the 10 patients (10 lesions) who developed post-BMS implantation VLST. In the DES group, sirolimuseluting stents (SES) were used in 12 lesions (92.3%), while a paclitaxel-eluting stent (PES) was used in one lesion. The interval from stent implantation to VLST onset was 1,750± 769 days in the DES group, compared with 3,223±1,379 days in the BMS group. Therefore, this period was significantly longer in the BMS group (p=0.003). The stent diameter was also significantly greater in the BMS group. Three patients (23.1%) in the DES group were treated with dual antiplatelet therapy (DAPT) at the time of VLST onset, compared with four patients (40.0%) in the BMS group (p= 0.38). The pre-diameter stenosis and mean minimal lumen diameter (MLD) were similar between the groups. Table 2 shows the OCT findings of the VLST lesions. In this study, we conducted an OCT analysis of 1,669 frames (9,557 struts) in DES patients and 1,407 frames (7,956 struts) in BMS patients. The proportion of uncovered struts was 4.5±6.2% in the DES group, compared with 0.2±0.3% in the BMS group (p=0.004), thus indicating significantly higher results in the DES group. Furthermore, the ratio of malapposed struts was 6.4±10.0% in the DES group, compared with 0.3±0.9% in the BMS group (p=0.002). The details of the patients with VLST in the DES and BMS groups are shown in Table 3 . Lesion numbers 10 and 11 in the DES group were from the same patient, who developed simultaneous stent occlusion. While all BMS patients exhibited almost complete covering of the stents, severe uncovered or severe malapposed struts were observed in four lesions (30.7%) in the DES patients. Intimal disruption oc- 
Results
Baseline and lesion characteristics
OCT findings
PCI procedure
The selection of the PCI strategy was made at the operator's discretion. The details of the procedure before and after OCT are described in Table 4 . Two DES-treated lesions were treated with thrombolysis alone after the OCT examination.
Discussion
Several large-scale registries have reported that the frequency of stent thrombosis post-DES implantation is 0.36-0.6% each year, with no attenuation observed within a fiveyear follow-up period (3) (4) (5) .
The mechanisms underlying the development of DESrelated VLST are complicated and have not been completely elucidated. However, analyses of postmortem pathology specimens and intravascular ultrasound (IVUS) research suggest that uncovered struts (delayed healing) and malapposed struts ( incomplete stent apposition ) are probable causes (10) (11) (12) (13) (14) (15) (16) . An increased duration of VLST onset of more than five years after stent implantation, even in BMS patients, has recently been reported; the mechanism for this phenomenon is considered to be the occurrence of neoatherosclerosis within the stent (20) . Via the effects of endothelial dysfunction, neoatherosclerosis causes foamy macro- phage infiltration and the formation of necrotic cores, leading to intimal disruption (21) . Because it has also been reported that neoatherosclerosis progresses more quickly in DES patients than in BMS patients, this process could also be a cause of VLST onset in DES patients.
Delayed healing and incomplete stent apposition
All BMS patients exhibited almost complete covering of the stents, with the proportion of uncovered struts being 0.2±0.3%. In the DES patients, severe uncovered and malapposed struts were observed in two (15.4%) and three lesions (23.1%), respectively. In these patients, delayed endothelialization led to thrombus formation on the surface of the stent struts, which may have caused VLST (Fig. 2) . Postimplantation positive remodeling may also be involved in the formation of malapposed struts, which is commonly caused by poor expansion during stent implantation. Positive remodeling can be perceived on peri-stent contrast staining (PSS) or as a coronary artery aneurysm during CAG testing. PSS was observed in one DES-treated lesion, although no coronary aneurysm was found.
The mechanism underlying stent malapposition may involve the presence of sirolimus in the polymer-coated area, causing an excessive local concentration (hypersensitivity re-action), leading to an inflammatory reaction accompanied by eosinophil infiltration between the stent and the blood vessels (13, 22, 23) . Stent malapposition may then cause thrombus formation accompanying enhanced coagulability in the gap between the stent and vascular wall. This hypothesis is supported by the fact that marked intimal proliferation occurs in BMS patients, and there have been no reports of BMS patients in whom the above pathological phenomenon has been noted.
Intimal disruption
Intimal disruption occurred in four lesions (30.8%) in the DES group and five lesions (50.0%) in the BMS group (p= 0.349). It is believed that plaque rupture after neoatherosclerosis formation caused VLST in these patients (Fig. 3) .
Lee et al. reported, in an IVUS study, that intimal disruption within stents was observed in 43.5% of 23 DES-related VLST patients (8) . Meanwhile, Ko et al. reported that intimal disruption was noted in 22.2% of 18 DES-related VLST patients (24) . The results of this study are consistent with the findings of these prior reports. Of the patients in whom intimal disruption occurred, two lesions in each of the DES and BMS groups did not exhibit severe intimal hyperplasia. This suggests that the presence of vulnerable plaque, rather than the degree of hyperplasia, is related to intimal weakening and tissue instability. Furthermore, no intimal disruption was observed, although severe intimal hyperplasia (percent plaque area of ! 60%) alone was present, in four lesions (30.8%) in the DES group, compared with five lesions (50.0%) in the BMS group. In these patients, VLST may have been caused by thrombus formation due to lumen stenosis resulting from severe hyperplasia. The OCT analysis in this study suggested that intimal hyperplasia or intimal disruption caused VLST in all patients in the BMS group. Therefore, it appears that VLST was caused by the occurrence of neoatherosclerosis after stent placement. However, in the DES group, neoatherosclerosis appeared to have caused eight lesions (61.5%), while uncovered struts (delayed healing) and malapposition appeared to have been involved in the formation of the other lesions.
Amabile et al. reported that in-stent neoatheroma (ISNA) was detected in 10 of 20 VLST patients. The authors proposed that ISNA should be recognized as the culprit lesion if the following criteria are fulfilled: (i) the presence of neoatherosclerotic tissue transformation within the stent; (ii) the presence of neointimal rupture within the stent; (iii) the absence of uncovered struts; and (iv) the absence of ruptured-cap atherosclerotic lesions proximal or distal to the stent (25) . Therefore, they considered that uncovered struts were not simultaneously present with ISNA in VLST le-sions. However, Kang et al. reported that, in 27 DES patients with VLST, neointimal rupture was seen in 17 cases (63%) and malapposition was noted in 14 cases (52%); both neointimal rupture and malapposition were observed in six cases (22%). Among the DES-treated lesions, 15 (56%) had at least one frame with uncovered struts, and 14 (52%) had at least one frame with malapposed struts (26) . Miyazaki et al. evaluated six VLST lesions with OCT and reported that uncovered struts were observed in all six VLST patients (19) . Hence, these previous studies revealed that, in some VLST lesions, both neoatheroma and malapposed or uncovered struts are observed simultaneously. Therefore, our OCT findings are consistent with those of previous reports.
High hopes surround the ability of next-generation stents to solve the unsolved issue of VLST accompanying DES implantation. It has been reported that second-generation everolimus-eluting stents are associated with fewer instances of thrombosis than first-generation stents (27) . Furthermore, because the immune reaction to durable polymers can cause stent thrombosis, bioabsorbable polymers (biodegradable stents) are now being used in next-generation stents (Nobori biolimus A9 eluting stent). In addition, reduced positive remodeling can be addressed by resolving drug-eluting and polymer coating problems in future studies.
Dual antiplatelet therapy (DAPT)
In the present study, three patients (23.1%) in the DES group and four patients (40.0%) in the BMS group were treated with dual antiplatelet therapy (DAPT). While it has been previously indicated that the discontinuation of DAPT can trigger VLST, it has also been reported that such discontinuation only leads to stent thrombosis within six months of stent implantation and is therefore not a predictive factor for an increased risk of stent thrombosis (28, 29) . Therefore, it appears unlikely that DAPT discontinuation directly affected our results.
Study limitations
The study is associated with a few limitations. First, the low frequency of VLST onset means that comparisons could only be made among a small number of patients. In addition, all comparisons were made between DES and BMS patients, and no comparisons were made with patients with normal coronary stenosis lesions.
Second, the OCT analysis may not have led to a completely accurate assessment. In particular, when conducting OCT, the aspiration catheter and/or balloon may have affected the wall shape. The presence of superficial thrombi also made it impossible to sufficiently observe the vascular lumen in some patients; therefore, not all struts could be assessed, and some instances of intimal disruption may have been missed.
Conclusion
In the present study, the OCT findings confirmed that severe intimal hyperplasia and intimal disruption can cause VLST in BMS placement patients. Our results also revealed the diversity of VLST lesions, suggesting that the presence of uncovered and malapposed struts, in addition to the above causes, can also induce VLST in DES placement patients. The causes of VLST in the DES group were more various and complicated than those observed in the BMS group.
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